Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval ...

The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous ...

Armed with new nods in asthma and adolescent eczema, Regeneron’s Dupixent keeps reeling in new biologics patients. But as phase 3 results in COPD loom, helmsman Len Schleifer warns that tapping into ...

The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decad ...

Paris: Sanofi has announced that the European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adult and ...

Please provide your email address to receive an email when new articles are posted on . Dupixent was approved in the European Union to treat severe atopic dermatitis in children aged 6 months to 5 ...

Dupixent is a blockbuster immunology drug that just keeps delivering for Sanofi and Regeneron, so it’s no surprise that the “franchise in a therapy” has got a new set of ads. Sanofi and Regeneron, ...

Morgan Stanley has downgraded Regeneron Pharmaceuticals (REGN) to equal-weight from overweight saying that the stock is ...

TRENTON, N.J. --U.S. regulators have approved the first powerful, injected medicine to treat serious cases of the skin condition eczema. The Food and Drug Administration on Tuesday approved Dupixent ...

The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...